Evidence map›Paper›PMID 39400017›Full record

ReviewCurrent medicinal chemistry2025

From Proteomics to Diagnosis: Biomarker Discovery in Tuberculosis Research.

Jiarong Yang, Jianhua Zheng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Discovery and validation of novel plasma protein biomarkers for severe tuberculosis patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiarong YangNHC Key Laboratory of Systems Biology of Pathogens, Chinese Academy of Medical Sciences & Peking Union Medical College, National Institute of Pathogen Biology and Center for Tuberculosis Research, Beijing, 102629, China.
Jianhua ZhengNHC Key Laboratory of Systems Biology of Pathogens, Chinese Academy of Medical Sciences & Peking Union Medical College, National Institute of Pathogen Biology and Center for Tuberculosis Research, Beijing, 102629, China.

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-037
6 · The paper itself

Abstract

Tuberculosis (TB) is a leading cause of death from a single infectious disease worldwide. Early and accurate diagnosis is advantageous for timely detection and prompt treatment, thereby reducing the risk of disease transmission, which is essential for effective TB control. Biomarkers provide a valuable resource for TB diagnosis. Proteomic technologies have emerged as a powerful tool in biomarker discovery. In this perspective, we explore how proteomic technologies contribute to the discovery of TB diagnostic biomarkers. We also address the challenges and discuss prospective methods to augment the performance of biomarkers in diagnosing TB.

Indexed as

BiomarkersProteomicsTuberculosisHumansMycobacterium tuberculosisBiomarkersactive tuberculosisbiomarkersdiagnosislatent tuberculosis infectionMycobacterium tuberculosisproteomicssmear microscopy.

Identifiers

PMID39400017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.